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The use of biomarkers of brain injury in pediatric neurocritical care has been explored
for at least 15 years. Two general lines of research on biomarkers in pediatric brain injury
have been pursued: (1) studies of “bio-mediators” in cerebrospinal fluid (CSF) of chil-
dren after traumatic brain injury (TBI) to explore the components of the secondary injury
cascades in an attempt to identify potential therapeutic targets and (2) studies of the
release of structural proteins into the CSF, serum, or urine in order to diagnose, monitor,
and/or prognosticate in patients with TBI or other pediatric neurocritical care conditions.
Unique age-related differences in brain biology, disease processes, and clinical applica-
tions mandate the development and testing of brain injury bio-mediators and biomarkers
specifically in pediatric neurocritical care applications. Finally, although much of the early
work on biomarkers of brain injury in pediatrics has focused on TBI, new applications
are emerging across a wide range of conditions specifically for pediatric neurocritical care
including abusive head trauma, cardiopulmonary arrest, septic shock, extracorporeal mem-
brane oxygenation, hydrocephalus, and cardiac surgery. The potential scope of the utility
of biomarkers in pediatric neurocritical care is thus also discussed.
Keywords: cerebrospinal fluid, abusive head trauma, shaken baby syndrome, neuron specific enolase, S100β, GFAP,
myelin basic protein, UCH-L1
INTRODUCTION
Serum or cerebrospinal fluid (CSF) biomarkers of brain injury
have been suggested as possible diagnostic adjuncts in neurocriti-
cal care since the groundbreaking work from the laboratory of Per
Vaagenes (Kjekshus et al., 1980; Vaagenes et al., 1980, 1984, 1986,
1987, 1988; Bohmer et al., 1983; Vaagenes, 1986) in experimental
and clinical cardiac arrest (CA), anoxic brain injury, stroke, and
open heart surgery over 30 years ago. Earlier work in the 1960s
concluded that serum creatine kinase, aspartate aminotransferase,
and lactate dehydrogenase were not helpful as brain injury bio-
markers (Dubo et al., 1967). However, in an often overlooked but
remarkably prescient series of reports, his team used creatine phos-
phokinase brain band (CPK-BB) as the primary biomarker, along
with CSF lactate dehydrogenase and aspartate aminotransferase
and found that levels of these markers increased in CSF across
these conditions. The studies included canine models of CA, and
patients with CA, anoxic brain injury, cardiac surgery, or stroke.
This was remarkably translational work for the early 1980s. They
also explored the possible theragnostic utility of CSF biomark-
ers in patients treated with hypothermia vs. normothermia after
CA (Vaagenes, 1986). Vaagenes called this approach “a chemical
biopsy of the brain” and indicated that it may be clinically useful
in prognosticating or in determining appropriate “levels of care.”
Although the development of brain injury biomarkers is certainly
challenging, it is unclear why we did not listen more carefully to
him and further pursue this line of investigation 30 years ago.
The use of biomarkers of brain injury in pediatric neurocritical
care has been explored for at least 15 years. We believe that studies
in pediatric populations and applications are essential. Although in
many cases, serum biomarkers of brain injury perform similarly in
adult and pediatric applications, it is important to recognize that
some biomarkers, show important age dependent differences in
normal values in biological samples including CSF or serum. The
most well recognized in this regard is S100B which exhibits high
levels during infancy. These developmental increases also appear
to be somewhat variable in magnitude and thus mandate that need
for age matched controls when using this biomarker (Portela et al.,
2002; Gazzolo et al., 2003). Thus, it is important to include the full
spectrum of pediatric age groups when testing new pediatric bio-
markers. Similarly, some disease processes exhibit age dependent
second injury mechanisms such as the propensity toward neu-
ronal apoptosis early in development. Brain injury biomarkers
can have unique applications in pediatric traumatic brain injury
(TBI) such as in detection of clinically silent brain injury in abu-
sive head trauma (AHT) (Berger et al., 2006b). Finally, the nature
of brain injury and its time course vary greatly across the spectrum
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of insults seen in pediatric neurocritical care and it is likely that
the serum or CSF biomarker signature generated for each insult
will differ. Our prior study of serum brain injury biomarker levels
in infants and children across neurological diseases in the PICU
confirmed that fact (Berger et al., 2006a), and represents an initial
step in this regard. These issues mandate the development and
testing of brain injury bio-mediators and biomarkers specifically
in pediatric applications.
In this review, we will begin with studies of bio-mediators and
biomarkers of brain injury in pediatric TBI and then broaden the
discussion to other key disease processes associated with brain
injury in the pediatric intensive care unit (ICU). This includes
AHT, CA, and other pediatric neurocritical care conditions where
brain injury biomarkers are showing promise.
EARLY STUDIES ON BIO-MEDIATORS AND BIOMARKERS OF BRAIN
INJURY IN PEDIATRIC TBI
Bell et al. (1997b) examined CSF levels of the cytokines
interleukin-6 (IL-6) and IL-10 in infants and children after
severe TBI (Glasgow coma scale score< 8) and reported marked
increases of both vs. controls. The levels of IL-6 in CSF were sim-
ilar to the levels of IL-6 in serum in separate children with septic
shock (Bell et al., 1997a), highlighting the surprising magnitude
of the “inflammatory response” in brain after TBI, and suggesting
that IL-6 might be useful as a biomarker of brain injury after TBI.
Most of the early work on biomarkers of brain injury in children
focused on TBI which is logical given its prevalence in children,
and the availability of CSF as a biological sample source with the
use of CSF diversion in the treatment of patients with severe TBI
including AHT (Kochanek et al., 2012a,b). In general, two lines
of research have been pursued: (1) studies of “bio-mediators” in
CSF of children after TBI to explore the secondary injury cas-
cade in an attempt to identify potential therapeutic targets and (2)
studies of the release of structural proteins into the CSF, serum,
or urine in order to diagnose, monitor, and/or prognosticate in
patients with TBI. Although there is overlap between what con-
stitutes a bio-mediator vs. a biomarker, the use of this construct
to categorize studies is helpful. Among those studies, we pub-
lished several seminal reports such as the aforementioned study
on IL-6, the first use of CSF biomarkers to examine the molec-
ular footprints of apoptotic neuronal death (Bcl-2, cytochrome
c) after pediatric TBI (Clark et al., 2000; Satchell et al., 2005),
and the first studies targeting use of serum biomarkers to aid in
making the diagnosis of silent brain injury in infants with AHT
(Berger et al., 2006b, 2009). We will discuss these and other recent
studies on bio-mediators and biomarkers in pediatric TBI. Finally,
in 2006, Berger et al. (2006a) published a study on the poten-
tial utility of three different serum biomarkers [neuron specific
enolase (NSE), S100β, and myelin basic protein (MBP)] in three
common pediatric neurocritical care diseases, namely, TBI, AHT,
and cardiopulmonary arrest. Subsequent to that publication, other
groups have published promising reports on the potential utility of
these and several other serum biomarkers to identify brain injury
in important diseases encountered in the pediatric ICU including
recent reports on septic shock, extracorporeal membrane oxygena-
tion (ECMO), hydrocephalus, and cardiac surgery (Cengiz et al.,
2008; Hsu et al., 2008; Bembea et al., 2011; Bhutta et al., 2012).
The potential scope of the utility of biomarkers in pediatric neur-
ocritical care will thus also be discussed. An overview of the topics
addressed in this review is provided in Figure 1.
DEFINING THE EVOLUTION OF SECONDARY DAMAGE IN
PEDIATRIC TBI USING CSF “BIO-MEDIATORS”
The concept that CSF could be used to assess bio-mediator sub-
stances involved in secondary injury mechanisms was suggested
as early as 1949 as shown for the neurotransmitters acetylcholine
and serotonin by Tower and McEachern (1949) and Sachs (1957)
in studies focused on clinical TBI (reviewed by Hayes et al., 1992).
An early review on the use of CSF bio-mediators of brain injury in
pediatric TBI provided initial rationale for the use of this approach
(Kochanek et al., 2000) and the potential value of this line of inves-
tigation has gained support. Although the control of intracranial
hypertension after severe TBI is important to prevent secondary
brain ischemia and herniation, recent studies have suggested the
need for additional therapies targeting other mechanisms of sec-
ondary damage. A multi-center randomized controlled trial (RCT)
of decompressive craniectomy in adults with severe TBI (Cooper
et al., 2011) showed that despite better control of raised ICP with
surgical decompression, outcomes were worse vs. medical man-
agement – which unlike surgery, may be treating both ICP and
other secondary injury mechanisms. Similarly, Mehta et al. (2010)
reported that despite highly successful control of ICP in infants
with severe TBI,∼50% of children <2 years of age still had unfa-
vorable long-term outcomes. Taken together, these studies suggest
that we need to define the pivotal molecular secondary injury
pathways after TBI and target them with novel therapies. In a
number of studies, we have used CSF bio-mediators for this pur-
pose and suggest potential therapeutic targets. Selected studies are
discussed below.
BIO-MEDIATORS OF NEURONAL DEATH
Early work in TBI suggested that neuronal death resulted from
necrosis either from the primary impact or secondarily from
ischemia-reperfusion during intracranial hypertension (reviewed
in Kochanek et al., 2000). However, brain tissue samples from
adults with severe TBI suggested that the molecular footprints of
apoptosis including Bcl-2, Bcl-xl, Bax, and/or cleavage of caspase-
3 were detectable in the initial days after severe TBI (Clark et al.,
1999). Subsequently, Clark et al. (2000) showed that increases in
CSF levels of the anti-apoptotic protein Bcl-2 were seen in infants
and children early after severe TBI and were correlated with sur-
vival. Satchell et al. (2005) followed up on that study and reported
that CSF levels of the pro-apototic protein cytochrome c were
increased in infants with severe TBI. Cytochrome c levels were
increased vs. control, and associated with mortality and AHT as
an injury mechanism. This suggested that victims of AHT might
represent a specific target population for the use of anti-apoptotic
therapies after pediatric TBI. However, it is difficult to determine
whether effects attributed to AHT are occurring independent of
young age, since most infants with severe TBI are victims of AHT.
Caspase-3 levels are also known to be much higher early in devel-
opment than in older children (or adults) based on pre-clinical
studies (Yakovlev et al., 2001). In addition, female gender was
associated with increased levels of cytochrome c after severe TBI
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FIGURE 1 | Overview of the approaches taken by our research team and
others in the application of bio-mediators and biomarkers of brain injury
to study pediatric neurocritical care. Two basic strategies have been
utilized, namely (1) studies using bio-mediators to study evolution of
secondary injury and define new therapeutic targets (shown in black), and (2)
studies of biomarkers largely of structural origin released from injured or dying
cells representing three major cellular components in the brain (i.e., neurons,
astrocytes, and axons) to serve as diagnostic or prognostic adjuncts. For the
studies of bio-mediators of secondary injury, this approach has been largely
carried out in traumatic brain injury (TBI) using assessment of cerebrospinal
fluid (CSF) that is drained as part of standard of care to reduce intracranial
pressure. In those studies, five major secondary injury pathways including
neuronal death, oxidative stress, traumatic axonal injury (TAI), inflammation,
and excitotoxicity have received the most investigation using this approach.
These pathways can ultimately lead to long-term disabilities and/or chronic
traumatic encephalopathy (CTE). For the studies of biomarkers (shown in
gray), although many biomarkers have been examined, five have been used in
the majority of studies including the neuronal markers neuron specific
enolase (NSE) and ubiquitin C-terminal hydrolase-L1 (UCH-L1), the astrocyte
markers S100β and glial fibrillary protein (GFAP), and the axonal injury marker
myelin basic protein (MBP). Both approaches have theragnostic applications.
The dotted lines reflect that recognition that some “bio-meditros” can serve
as biomarkers and vice versa. Please see text for additional details. AHT,
abusive head trauma; ECMO, extracorporeal membrane oxygenation.
in infants and children, which is consistent with the predomi-
nance of apoptosis as a cell death pathway after exposure of female
vs. male neurons to neurotoxins in cell culture (Du et al., 2009).
Increases in the CSF levels of cytochrome c after pediatric TBI
and its association with AHT and female gender were confirmed
in a study examining biomarkers of apoptosis vs. necrosis (Au
et al., 2012). These studies suggest that apoptotic neuronal death
may represent a therapeutic target in pediatric TBI, particularly
in infants. Studies in experimental models of TBI suggested that
levels of cleavage products of αII Spectrin might be able to aid in
differentiating apoptotic vs. necrotic neuronal death mechanisms
in TBI (Pike et al., 1998a,b). αII Spectrin is cleaved by either cal-
pain during necrosis to 145 and 150 kDa degradation products
or by caspase-3 during apoptosis to a 120 kDa degradation prod-
uct. And this approach has also been used to estimate the time
course and necrotic vs. apoptotic neuronal death in adult patients
with severe TBI using CSF analysis (Pineda et al., 2007). A pre-
dominantly necrotic profile was seen in adults in the initial 5 days
after injury. Monitoring markers of neuronal apoptosis after TBI
thus could be particularly important in children and is an area
for future clinical work. Studies in experimental models of TBI
suggest that other neuronal death pathways may play important
roles including autophagy, necroptosis, and pyroptosis (You et al.,
2008; Du et al., 2009; Adamczak et al., 2012). Unique biomark-
ers of these processes are also needed to define the quantitative
contribution of these pathways to the evolution of neuronal death
after TBI and other disorders in neurocritical care. The studies
on neuronal death mechanisms in pediatric TBI also highlight
the fact that pediatric TBI includes the special condition of AHT.
Although TBI resulting from motor vehicle accidents, falls, and
other mechanisms seen in both children and adults produces het-
erogeneous pathologies, AHT adds considerably to this problem.
In addition to routine TBI presentations such as contusion, sub-
dural hematoma, or diffuse axonal injury, AHT often presents
with unique pathologies (Ichord et al., 2007). For example, in
many cases the CT findings are consistent with hypoxic ischemic
encephalopathy (HIE) – possibly from apnea at the scene, delay
in presentation, or cervical nerve root injury. In addition, AHT
is often repetitive, and thus both acute and chronic TBI can be
superimposed. Given these factors, serum and CSF bio-mediators
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and biomarkers of brain injury may have special value in AHT – as
shown in a number of studies discussed in this review.
OXIDATIVE STRESS BIO-MEDIATORS AND BIOMARKERS AFTER
PEDIATRIC TBI
Another mechanism that may represent an important therapeu-
tic target is oxidative stress. Bayır et al. (2002) published the first
comprehensive report on CSF markers of oxidative stress after
severe TBI in children. Strong evidence for major losses of antiox-
idants such as ascorbate was seen along with increases in levels
of markers of oxidative damage such as F2-isoprostane. During
the initial week after injury, a progressive reduction of CSF levels
of ascorbate was noted. This suggests ongoing oxidative stress in
children after severe TBI. Mitochondrial dysfunction was shown
to occur in brain tissue samples from patients with severe TBI
(Verweij et al., 2000) and may serve as a key source for free radicals
(Kagan et al., 2004, 2009). In an experimental model of pedi-
atric TBI, selective oxidation of the mitochondrial lipid cardiolipin
was seen early after injury, suggesting that mitochondria are an
initial source of free radicals (Bayır et al., 2007). Given that car-
diolipin oxidation is intimately linked to release of cytochrome
c, oxidative stress may be critically linked to apoptotic neuronal
death after TBI (Kagan et al., 2004, 2009). Antioxidants that tar-
get mitochondria may thus represent a logical strategy to target
apoptotic neuronal death, which could be particularly important
in pediatric TBI. Consistent with that hypothesis, mitochondrial
targeting has shown impressive success in experimental models
of pediatric TBI (Ji et al., 2012). CSF levels of antioxidants or
oxidized cardiolipin, as assessed by oxidative lipidomics, might
also represent excellent biomarkers for theragnostic use and merit
future study (Tyurin et al., 2008; Kagan et al., 2009; Ji et al., 2012).
Finally, in a theragnostic application focused on oxidative stress in
pediatric TBI, mild therapeutic hypothermia markedly attenuated
the increase in CSF levels of markers of oxidative stress, suggest-
ing that hypothermia mitigates this mechanism in patients (Bayır
et al., 2009).
BIO-MEDIATORS OF NEUROINFLAMMATION
Another secondary injury mechanism that has been studied in
pediatric TBI using CSF levels of bio-mediators is inflamma-
tion. Early work on CSF bio-mediators in pediatric TBI focused
on inflammatory cytokines (Bell et al., 1997b). Subsequently,
CSF levels of a number of inflammatory mediators were mea-
sured (Whalen et al., 2000; Amick et al., 2001; Robertson et al.,
2001b; Han et al., 2002; Tong et al., 2004; Buttram et al., 2007;
Fink et al., 2008; Salonia et al., 2010). A complete description
of those studies is beyond the scope of this review; however,
several points are noteworthy. First, severe TBI is consistently
accompanied by a robust increase in CSF levels of cytokines
and chemokines, particularly IL-6 and IL-8 (Bell et al., 1997a,b;
Whalen et al., 2000; Amick et al., 2001; Buttram et al., 2007).
Second, the inflammatory response is complex and contributes
detrimental and beneficial effects depending on timing (Scher-
bel et al., 1999). It thus represents a perplexing therapeutic
target. Third, multiplex technology has been useful to study
cytokines and chemokines after TBI – allowing multiple medi-
ators to be quantified in a single sample. A multiplex approach
was used by Buttram et al. (2007) to test the effect of thera-
peutic hypothermia on CSF levels of cytokines and chemokines
after severe TBI in children. Many inflammatory mediators
were increased, but, surprisingly hypothermia had only mod-
est effects on them. Cellular effectors of neuroinflammation
include microglia, macrophages, and T-lymphocytes, and addi-
tional CSF markers are needed to determine if aspects of
the inflammatory process can be therapeutically targeted in
pediatric TBI.
BIOMARKERS AND BIO-MEDIATORS OF TRAUMATIC AXONAL INJURY
Traumatic axonal injury (TAI) represents a mechanism of sec-
ondary damage that has been receiving increased attention
recently, particularly as new imaging modalities are revealing the
scope of this process (Tong et al., 2004; Babikan et al., 2005; Gal-
loway et al., 2008). TAI was once believed to represent largely a
primary injury process, however, the importance of “secondary
axotomy” resulting from calcium accumulation and mitochon-
drial failure in axons has gained support (Smith et al., 2013). In
pediatric TBI, Su et al. (2012) reported on this pathway using
CSF levels of MBP, showing marked and sustained increases in
this biomarker. The levels were on the order of ∼1000-fold higher
than control, suggesting a major contribution of TAI. Drugs tar-
geting TAI have not been tested in pediatric TBI, although calpain
antagonists, cyclosporine-A, and FK506 have shown promise in
experimental models (Smith et al., 2013). In the study by Su et al.
(2012) mild hypothermia did not reduce CSF levels of MBP after
severe TBI. Therapies that target TAI are needed and theragnostic
use of a TAI biomarker such as MBP is logical. Pre-clinical stud-
ies suggest that there may be more injury of unmyelinated than
myelinated axonal fibers (Reeves et al., 2005), and thus, new CSF
biomarkers of unmyelinated axons are needed.
Excitotoxicity is a widely accepted secondary injury mechanism
early after TBI. It could underlie early post-traumatic seizures and
subclinical status epilepticus which are important in infants and
young children (Liesemer et al., 2011). Early work on excitotoxi-
city in pediatric TBI was carried out by Ruppel et al. (2001) who
reported marked increases in CSF levels of glutamate and other
excitatory amino acids after severe injury. The increases peaked
early in most patients and were associated with AHT. Robertson
et al. (2001a) showed that the increases in CSF glutamate were
coupled to retaliatory increases in levels of the endogenous anti-
convulsant adenosine. Excitotoxicity may also mediate synaptic
injury and one study showed marked increases in CSF levels of
the synaptic protein α-synuclein after severe TBI in children (Su
et al., 2010). α-Synuclein levels were increased ∼5-fold early after
injury vs. control and progressed to levels ∼10-fold higher over
the first week. A hot area of research in TBI is in defining the link
between acute injury and the development of chronic traumatic
encephalopathy (CTE) (DeKosky et al., 2010). TBI is linked to a
variety of neurodegenerative diseases including Parkinson’s dis-
ease (PD). Deposition of α-synuclein aggregates in Lewy bodies in
PD suggests a link to this mechanism. Although this is an area of
intense study in adults, particularly with mild repetitive TBI, there
has been little study of this association in children. This is a vital
area of future research for TBI biomarkers in pediatrics given the
role of sports concussion and its link to CTE.
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SERUM BIOMARKERS IN PEDIATRIC TBI AND
CARDIOPULMONARY ARREST
DIAGNOSIS AND PROGNOSIS IN TBI
Building on the work in CSF, studies on the potential application
of serum biomarkers of brain injury in pediatric neurocritical
care began to emerge and initially focused on TBI and cardiopul-
monary arrest. These conditions represent two of the most com-
mon disease processes encountered in pediatric neurocritical care
and were thus logical targets for initial work on serum biomarkers.
For diagnostic and prognostic indications, the approach focused
on the use of proteins that are largely structural in nature and
as unique as possible to the CNS. Most of the studies in pedi-
atrics have centered around five biomarkers, namely, the neuronal
markers NSE and ubiquitin C-terminal hydrolase-L1 (UCH-L1),
the astrocyte markers S100β and glial fibrillary protein (GFAP),
and the axonal injury marker MBP. After demonstrating robust
increases in NSE and S100β in CSF in infants and children with
severe TBI (Berger et al., 2002), Berger et al. (2005) measured
serum levels of NSE, S100β, and MBP in 100 infants and children
with TBI in cases of varying severity. All three biomarkers showed
significant increases vs. controls, with sensitivity and specificity
of initial values, for example, of 71 and 64% (NSE) and 77 and
72% (S100β). This suggested promise for the use of these serum
biomarkers as diagnostic adjuncts in severe pediatric TBI. The
biomarkers were also increased in many children who presented
with a GCS score of 15 suggesting possible utility across injury
severities – although a comprehensive study of serum biomark-
ers in mild TBI in children remains to be completed. Fraser et al.
(2011) also explored the potential use of the biomarker GFAP in
severe TBI in children. Serum GFAP levels measured on day 1
correlated with Pediatric Cerebral Performance Category scores
assessed at 6 months. GFAP may also thus represent a potentially
useful serum biomarker of brain injury in pediatric neurocriti-
cal care. Finally, Berger et al. (2012) recently studied the potential
utility of serum levels of UCH-L1 and αII-SDP in pediatric TBI.
UCH-L1 and αII-SDP levels were increased in cases of moderate
or severe (but not mild) TBI and were correlated with Glas-
gow outcome scale score. These correlations were stronger than
those for NSE, S100β, and MBP. Taken together, these studies
suggest promise for a number of serum biomarkers in diagnos-
tic and prognostic applications across the injury spectrum in
pediatric TBI.
DIAGNOSTIC ADJUNCT IN AHT
An important subgroup of patients with TBI for potential utility
of serum biomarkers is cases of AHT – particularly infants with
mild injury in whom the diagnosis may be missed and confused
with conditions such as colic or gastroenteritis (Jenny et al., 1999).
Based on a series of reports, NSE and MBP were shown to be the
most potentially useful as screening tools to identify brain injury
in well-appearing infants with clinically silent AHT (Berger et al.,
2006b). Those studies led to the development of an NIH-funded
prospective case-control study on the use of serum biomarkers
for this purpose that has now entered nearly 900 infants. Stud-
ies are also ongoing examining the utility of GFAP and UCH-L1
in this setting. We also carried out a study of the application
of proteomics (2-dimensional gel electrophoresis) on the injury
response in AHT and compared it to non-abusive mechanisms
of TBI in infants and young children (Gao et al., 2007). Several
unique aspects of the proteomic injury profile were seen in AHT,
notably, a reduced acute phase response. Infants who were victims
of AHT had CSF proteomic profiles with reduced levels of acute
phase reactants such as haptoglobin and complement components
vs. children with TBI from other causes such as motor vehicle
accidents. This could reflect a delay in presentation or represent a
consequence of repeated injury often seen in cases of AHT. We also
used a Multiplex approach in an attempt to define a combination
or panel of serum biomarkers with high sensitivity and specificity
to detect silent brain injury in infants with AHT (Berger et al.,
2009). In that study, vascular cellular adhesion molecule (VCAM)
and IL-6, used together, could discriminate the AHT vs. control
with a sensitivity and specificity of 87 and 90%, respectively, when
evaluated in an appropriate pediatric population to target missed
AHT. Further studies using combinations or panels of biomarkers
are needed in AHT and across the relevant diseases in pediatric
neurocritical care.
SERUM BIOMARKERS OF BRAIN INJURY IN PEDIATRIC
CARDIOPULMONARY ARREST
We also carried out, to our knowledge, the first comparative study
of serum levels of NSE, S100β, and MBP in critically ill infants and
children after TBI,AHT, and cardiopulmonary arrest (Berger et al.,
2006b). Distinct temporal profiles were seen for each of these con-
ditions. TBI showed the largest acute increases in serum biomarker
levels likely reflecting immediate damage from the primary injury.
In cardiopulmonary arrest and AHT, delayed increases in the neu-
ronal death marker NSE suggested its (or other neuronal death
markers) potential utility for prognostic and theragnostic appli-
cations, and for the need to evaluate therapies targeting delayed
neuronal death in cardiopulmonary arrest and AHT. Several stud-
ies in neonatal HIE from birth asphyxia have quantified serum
biomarkers including S100β and NSE (Massaro et al., 2012; Roka
et al., 2012). In 25 infants treated with either hypothermia or
normothermia, serum S100β levels were lower in the hypother-
mia group and both S100β and NSE levels were higher in infants
with worse outcome (Roka et al., 2012). In a larger study of 75
infants with neonatal encephalopathy and treated with hypother-
mia, S100β and NSE were again shown to be higher in patients
with unfavorable outcome (Massaro et al., 2012). This suggests
that these biomarkers are useful even if hypothermia is used in
the treatment regimen. The astrocyte marker GFAP has also been
shown to be increased in serum early after injury in neonates
with HIE (Ennen et al., 2011). In preliminary studies, we reported
use of three serum biomarkers NSE, S100β, and MBP as aids in
prognostication in pediatric CA and observed outstanding per-
formance based on receiver operator characteristic analysis (Fink
et al., 2011). Several time points were employed, but 24 h val-
ues for NSE and S100β with cut points of 0.008 or 53.10 ng/mL
exhibited high probability for classifying good vs. poor outcome
in infants and children. This finding was seen despite the fact that
there was heterogeneity in the etiologies of the arrests. Studies of
the effect of mild hypothermia on biomarker levels and outcome
are also ongoing including assessment of the efficacy of 24 vs.
72 h of hypothermia. Studies of the potential utility of UCH-L1 in
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pediatric CA are also ongoing. For additional discussion of serum
biomarkers across adult and pediatric TBI and CA, the reader is
referred to a prior review (Kochanek et al., 2000).
BRAIN INJURY BIOMARKERS ACROSS OTHER PEDIATRIC
NEUROCRITICAL CARE DIAGNOSES
There have been a number of new applications of brain injury
bio-mediators and biomarkers in pediatric neurocritical care. We
will highlight several recent and promising studies in this regard
in septic shock, ECMO, hydrocephalus, and cardiac surgery.
SERUM BIOMARKERS OF BRAIN INJURY IN PEDIATRIC SEPTIC SHOCK
Hsu et al. (2008) assessed serum levels of S100β, NSE, and GFAP
over the initial week of presentation in 24 children with sep-
tic shock and reported substantial (∼10 and 20-fold) increases
in S100β and NSE respectively, despite lack of focal neurological
deficits on exam. However, continuous EEG revealed moderate to
severe encephalopathy in the patients. Biomarker levels were low
early after sepsis and peaked at 5–7 days, contrasting TBI or CA. It
is unclear whether these increases reflect permanent or transient
damage, are associated with any long-term neurological morbidity,
or reflect increases from extracerebral sources (Redl et al., 2008).
However, this study should serve as an excellent foundation for
future work in this area.
SERUM BIOMARKERS OF BRAIN INJURY DURING EXTRACORPOREAL
MEMBRANE OXYGENATION
Bembea et al. (2011) explored the use of plasma GFAP levels in 22
pediatric patients treated with ECMO for respiratory failure, car-
diac failure, CA, or sepsis. Infants admitted to the ICU but without
neurological injury served as controls. Seven infants treated with
ECMO developed neurological complications including intracra-
nial hemorrhage, cerebral edema, or brain death. Peak GFAP levels
were ∼50-fold higher in these infants. Several temporal patterns
were seen including progressive increases, or increases at single
time points. The extracorporeal-CPR group was at highest risk for
brain injury and increased plasma GFAP levels. A commentary
on this report suggested the need for rigorous biokinetic analy-
ses and the development of standardized assays for GFAP (Hayes
et al., 2011). Children on ECMO are a perfect group for use of
serum brain injury biomarkers given the difficulty in routine brain
imaging during ECMO.
CSF BIOMARKERS IN PEDIATRIC HYDROCEPHALUS
Cengiz et al. (2008) studied the application of CSF biomarkers
of brain injury to another common diagnosis in pediatric neur-
ocritical care, namely hydrocephalus. CSF levels of the neuronal
injury marker cleaved-tau protein were assessed in 11 children
with hydrocephalus requiring shunt placement or revision vs. val-
ues in controls. Cleaved-tau is a marker of neuronal damage or
turnover formed by the proteolytic cleavage of the structural pro-
tein microtubule associated protein-tau (MAP-tau). Cleaved-tau
CSF levels were increased in patients with hydrocephalus and cor-
related with duration of symptoms; ∼75% of the patients had
signs of increased ICP before surgery. Tau-cleavage products are
promising biomarkers of CTE and thus this study may represent a
valuable early report on this topic in children relevant to TBI.
SERUM BIOMARKERS OF BRAIN INJURY–THERAGNOSTIC
APPLICATION IN CARDIOPULMONARY BYPASS
Finally, several groups have tested serum biomarkers of brain
injury in the setting elective cardiac surgery in children (Abdul-
Khaliq et al., 2000; Ali et al., 2000; Matheis et al., 2000; Lindberg
et al., 2003; Lardner et al., 2004; Liu et al., 2009; Bhutta et al.,
2012). Although a complete review of those studies is beyond
the scope of this review, several studies have explored the ther-
agnositc use of brain injury biomarkers after cardiac surgery
in children. In an RCT of ketamine (2 mg/kg IV, n= 13) vs.
placebo (n= 11) before surgery in infants, plasma levels of NSE,
S100β, cytokines, and C-reactive protein were assessed (Bhutta
et al., 2012). C-reactive protein levels were lower with treat-
ment, although whether this reflected differences in brain injury
was unclear. Treatment reduced injury as reflected by choline
and glutamate plus glutamine/creatine levels assessed by mag-
netic resonance spectroscopy (MRS) in frontal white matter, but
no differences between groups were seen on behavioral test-
ing post-operatively. A combination of serum biomarkers with
MRS may represent a useful theragnostic approach in acute brain
injury. This strategy is being used to study the effect of 24 vs.
72 h of hypothermia in pediatric CA (Fink et al., 2011). Math-
eis et al. (2000) used serum levels of S100β to show increased
oxidative injury after uncontrolled vs. controlled re-oxygenation
after cardiac surgery in infants. Abdul-Khaliq et al. (2000) used
S100β to study the effect of treatment with sodium nitroprus-
side in 25 neonates after cardiac surgery and reported reduc-
tions in serum levels of this biomarker with treatment. Similar
approaches have been taken for other therapies after cardiac
surgery in children including corticosteroids (Lindberg et al.,
2003).
CONCLUSIONS
It is an exciting time for biomarker development and exploration
of bio-mediators in pediatric neurocritical care and rewarding that
after over 15 years of work in this area, use of these tools may
become standardized and incorporated into routine clinical use
for diagnosis, prognosis and other aspects of patient management.
Assessment of bio-mediators and biomarkers in CSF and serum is
also helping to define therapeutic targets and provide theragnostic
value in monitoring treatment efficacy. Brain injury biomarkers
may also guide patient stratification for clinical trials – to help
define the best sample for future RCTs or help show treatment
effects. This could be important given the many failures of trials
in TBI and the heterogeneity of this and other conditions in pedi-
atric neurocritical care. We look forward to the development of
point of care technology for brain injury biomarker applications
in pediatric neurocritical care.
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